izpis_h1_title_alt

Large-scale transcriptomics-driven approach revealed overexpression of CRNDE as a poor survival prognosis biomarker in glioblastoma
ID Sorokin, Maxim (Avtor), ID Raevskiy, Mikhail (Avtor), ID Zottel, Alja (Avtor), ID Šamec, Neja (Avtor), ID Skoblar Vidmar, Marija (Avtor), ID Matjašič, Alenka (Avtor), ID Zupan, Andrej (Avtor), ID Mlakar, Jernej (Avtor), ID Suntsova, Maria (Avtor), ID Kuzmin, Denis V. (Avtor), ID Buzdin, Anton A. (Avtor), ID Jovchevska, Ivana (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (4,17 MB)
MD5: FDB705B42BE8A778F9BDFFACC6367079
URLURL - Izvorni URL, za dostop obiščite https://www.mdpi.com/2072-6694/13/14/3419 Povezava se odpre v novem oknu

Izvleček
Glioblastoma is the most common and malignant brain malignancy worldwide, with a 10-year survival of only 0.7%. Aggressive multimodal treatment is not enough to increase life expectancy and provide good quality of life for glioblastoma patients. In addition, despite decades of research, there are no established biomarkers for early disease diagnosis and monitoring of patient response to treatment. High throughput sequencing technologies allow for the identification of unique molecules from large clinically annotated datasets. Thus, the aim of our study was to identify significant molecular changes between short- and long-term glioblastoma survivors by transcriptome RNA sequencing profiling, followed by differential pathway-activation-level analysis. We used data from the publicly available repositories The Cancer Genome Atlas (TCGA; number of annotated cases = 135) and Chinese Glioma Genome Atlas (CGGA; number of annotated cases = 218), and experimental clinically annotated glioblastoma tissue samples from the Institute of Pathology, Faculty of Medicine in Ljubljana corresponding to 2-58 months overall survival (n = 16). We found one differential gene for long noncoding RNA CRNDE whose overexpression showed correlation to poor patient OS. Moreover, we identified overlapping sets of congruently regulated differential genes involved in cell growth, division, and migration, structure and dynamics of extracellular matrix, DNA methylation, and regulation through noncoding RNAs. Gene ontology analysis can provide additional information about the function of protein- and nonprotein-coding genes of interest and the processes in which they are involved. In the future, this can shape the design of more targeted therapeutic approaches.

Jezik:Angleški jezik
Ključne besede:glioblastoma, noncoding RNA, long-term survival, CRNDE, RNA sequencing
Vrsta gradiva:Članek v reviji
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:MF - Medicinska fakulteta
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2021
Št. strani:18 str.
Številčenje:Vol. 13, iss. 14, art. 3419
PID:20.500.12556/RUL-135720 Povezava se odpre v novem oknu
UDK:616-006
ISSN pri članku:2072-6694
DOI:10.3390/cancers13143419 Povezava se odpre v novem oknu
COBISS.SI-ID:69980163 Povezava se odpre v novem oknu
Datum objave v RUL:29.03.2022
Število ogledov:940
Število prenosov:139
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Cancers
Skrajšan naslov:Cancers
Založnik:MDPI
ISSN:2072-6694
COBISS.SI-ID:517914137 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:08.07.2021

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:glioblastom, nekodirajoča RNA, dolgoročno preživetje

Projekti

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:Z3-1869
Naslov:Razvoj anti-FREM2 nanotelesa in njegova uporaba pri ciljanju glioblastomskih celic

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:BI-RU 19/20-005

Financer:Drugi - Drug financer ali več financerjev
Program financ.:OmicsWay

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Russian Federation, Ministry of Science and Higher Education
Številka projekta:075-15-2020-926
Naslov:Digital biodesign and personalized healthcare

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj